Anna Marie Mulligan



  1. Mrkonjic M, Berman H, Done S, Youngson B, Mulligan A. Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. J Clin Pathol. 2019;72:120-132 pubmed publisher
  2. Johnson N, Dudbridge F, Orr N, Gibson L, Jones M, Schoemaker M, et al. Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Res. 2014;16:R51 pubmed publisher
    ..These associations are likely mediated via an effect on circulating hormone levels. ..
  3. Angarita F, Chesney T, Elser C, Mulligan A, McCready D, Escallon J. Treatment patterns of elderly breast cancer patients at two Canadian cancer centres. Eur J Surg Oncol. 2015;41:625-34 pubmed publisher
    ..Until age-specific recommendations are available physicians must use clinical judgement and assess the tumour biology with the patient's comorbidties to make the best choice. ..
  4. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Res. 2015;17:61 pubmed publisher
    ..This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects. ..
  5. Pirie A, Guo Q, Kraft P, Canisius S, Eccles D, Rahman N, et al. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Res. 2015;17:58 pubmed publisher
    ..Larger studies from multinational collaborations are necessary to increase the power to detect associations, between common variants and prognosis, at more stringent significance levels. ..
  6. Silvestri V, Barrowdale D, Mulligan A, Neuhausen S, Fox S, Karlan B, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18:15 pubmed publisher
    ..e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. ..
  7. Forse C, Agarwal S, Pinnaduwage D, Gertler F, Condeelis J, Lin J, et al. Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer. 2015;15:483 pubmed publisher
    ..There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population. ..
  8. Petridis C, Brook M, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18:22 pubmed publisher
    ..0x10(-8). In conclusion, this study provides the strongest evidence to date of a shared genetic susceptibility for IDC and DCIS. Studies with larger numbers of DCIS are needed to determine if IDC or DCIS specific loci exist. ..